The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)

• Status: Terminated
• Trial end date: 2009-09-02
• Target enrollment: 0
• Participant gender: All

Summary

to assess the effect of treatment with Sitagliptin (MK0431) on HbA1c (Hemoglobin A1c) and the safety and tolerability of Sitagliptin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Patients Who Are 18 Years Of Age With Type 2 Diabetes Mellitus Who Are Either:

• Not On Antihyperglycemic (AHa) Medication (Off For At Least 2 Months)

• Or On A Single AHa